Skip to content

Hero image: A woman and clinician discussing a personalized PCOS care plan in a calm consultation

All insights

Hormonal health

PCOS Across the Life Course: Diagnosis, Metabolic Health and Individualized Care

12 min readEvidence synthesis
Read the evidence

The question in focus

A guideline-based guide to polycystic ovary syndrome covering diagnosis, symptoms, fertility, mental health and long-term metabolic care.

Evidence at a glance

10-13%

estimated global prevalence of PCOS among reproductive-aged women

WHO also estimates that up to 70% of affected women are undiagnosed. Estimates vary with diagnostic criteria, age and population. [1]

Polycystic ovary syndrome

PCOS is more than ovarian appearance

Polycystic ovary syndrome is a chronic endocrine and metabolic condition with varied presentations. WHO estimates that it affects 10% to 13% of reproductive-aged women and that up to 70% may be undiagnosed. Symptoms can include irregular or absent periods, signs of androgen excess such as unwanted hair growth or acne, difficulty conceiving and metabolic concerns. Ovarian cysts are not required for diagnosis. [1]

The name can therefore be misleading. Some people have polycystic ovarian morphology without the syndrome, while others meet diagnostic criteria without that ultrasound appearance. The 2023 international guideline emphasizes accurate diagnosis, avoiding unnecessary tests, emotional wellbeing and care across reproductive, metabolic and pregnancy outcomes. It includes 254 recommendations and practice points developed with international professional and consumer input. [2][4]

  • Symptoms and priorities can change across adolescence, fertility treatment, pregnancy and later life.
  • Weight is not a diagnostic criterion.
  • A normal ultrasound does not automatically exclude PCOS.

Diagnosis requires criteria and exclusion of alternatives

In adults, diagnosis generally requires at least two of three features after excluding other causes: clinical or biochemical hyperandrogenism, ovulatory dysfunction reflected by irregular cycles, and polycystic ovarian morphology. The 2023 guideline allows appropriately measured anti-Müllerian hormone as an alternative to ultrasound for defining polycystic ovarian morphology in adults, but not as a single diagnostic test. [2][3]

Alternative explanations can include thyroid disease, hyperprolactinemia, nonclassic congenital adrenal hyperplasia, hypothalamic amenorrhea and, when androgen levels or progression are marked, androgen-secreting conditions or severe insulin resistance syndromes. Adolescents need special caution because irregular cycles and acne can be part of normal pubertal development. The guideline does not recommend ultrasound or AMH for adolescent diagnosis. [3]

  • Document cycle pattern using time since menarche.
  • Use validated androgen assays when biochemical testing is needed.
  • Investigate rapid virilization or markedly elevated androgen levels promptly.
  • Avoid repeatedly measuring insulin in routine care without a clear indication.

Care should follow the person's priorities

There is no single PCOS treatment because the relevant outcomes differ. Cycle regulation and endometrial protection, acne or unwanted hair, fertility, sleep, mood and metabolic risk may require different strategies. Lifestyle support should be respectful, sustainable and free from weight stigma. The international guideline notes that healthy lifestyle has benefits even without weight loss and does not identify one diet composition as superior for all people with PCOS. [2]

Combined oral contraceptives can be considered for irregular cycles or hyperandrogenic symptoms when appropriate. Metformin is used particularly for metabolic indications and in selected cycle or fertility contexts. Anti-androgen therapy requires reliable contraception when pregnancy is possible because of fetal risk. Decisions depend on contraindications, goals, tolerability and local prescribing guidance. [2][5]

  • Agree which outcome matters most now.
  • Review response and adverse effects rather than continuing an ineffective plan.
  • Address dermatologic and hair symptoms without minimizing their psychological impact.

Fertility treatment is stepwise

PCOS is a common cause of anovulatory infertility, but many people conceive spontaneously or with treatment. Before ovulation induction, care should assess other fertility factors and optimize preconception health. The 2023 guideline recommends letrozole as first-line pharmacological ovulation induction for anovulatory infertility in PCOS when no other infertility factor is present, subject to local approval and clinical suitability. [2][3]

Other options can include clomiphene citrate, metformin in selected circumstances, gonadotropins or ovarian surgery, with IVF generally reserved for failure of first- or second-line therapy or another indication. PCOS is considered a higher-risk condition in pregnancy, with increased risk of gestational diabetes and hypertensive complications, so appropriate antenatal assessment matters. [3]

  • Confirm whether ovulation is the main fertility barrier.
  • Discuss multiple-pregnancy risk with ovulation induction.
  • Plan glucose and blood pressure assessment before and during pregnancy.
  • Do not promise a fixed time to pregnancy.

Mental and long-term health belong in routine care

The international guideline recommends screening for depression in adults and adolescents with PCOS and for anxiety in adults, followed by appropriate assessment, treatment and referral when indicated. Body image, eating disorders, infertility stress and weight stigma can all affect care. Screening should occur within a system able to respond, not as an isolated questionnaire. [2]

Long-term follow-up should include glycemic status, cardiovascular risk factors, sleep symptoms and cycle-related endometrial risk, with timing individualized. WHO describes PCOS as a chronic metabolic condition that persists beyond reproductive years. [1] ACOG similarly emphasizes that treatment can manage symptoms and support fertility even though it does not cure the syndrome. [6]

  • Assess glycemic status at diagnosis and repeat according to individual risk.
  • Ask about sleep apnea symptoms, mood and eating concerns.
  • Ensure prolonged amenorrhea has a plan for endometrial protection.
  • Revisit goals as life stage and health priorities change.

What the evidence cannot yet answer

  • Prevalence varies with diagnostic criteria, age and sampling method.
  • Many PCOS recommendations rely on low to moderate certainty evidence.
  • Long-term cardiovascular event data are less certain than evidence for risk factors.
  • This overview cannot determine an individual's diagnosis or medication suitability.

Questions worth taking into care

  1. Which diagnostic criteria are met and which alternative causes were excluded?
  2. What symptom or future health goal matters most right now?
  3. Has mental health been assessed with a response pathway?
  4. Is there a plan for cycle protection, metabolic monitoring and pregnancy care?
  5. Are recommendations respectful and free from weight stigma?

Source record

Evidence used in this review

Sources were selected for clinical authority, methodological relevance and traceability. Links open the original guidance, public-health record or research publication.

  1. [1]
    Polycystic ovary syndrome

    World Health Organization · 2026

  2. [2]
  3. [3]
  4. [4]
  5. [5]
  6. [6]
    Polycystic Ovary Syndrome

    American College of Obstetricians and Gynecologists · 2024

Editorial standard

This evidence synthesis is for general information. It does not diagnose a condition or replace care from a qualified health professional. Treatment choices depend on individual history, examination, local guidance and informed preference. Emergency or rapidly worsening symptoms need urgent local medical assessment.